Who
Matthew Lang
COO & Gc
Company insider
Files Form 4 as: COO & Gc, Structure Therapeutics; Chief Legal Officer, Metsera; Chief Business Officer, Lyell Immunopharma; General Counsel & Corp. Secy., Myovant Sciences.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 22
- Bought
- $0
- Sold
- $4.0M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 17 Jul 2017
- Last trade
- 15 Apr 2026
- Last filed
- 23 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Apr 2026filed 23 Apr 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —184,614 at $0.00 | filing |
| 15 Apr 2026filed 23 Apr 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,776 at $0.00 | filing |
| 15 Apr 2026filed 23 Apr 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,776 at $0.00 | filing |
| 15 Apr 2026filed 23 Apr 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —184,614 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code A | —12,500 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —46,875 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —325,000 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metsera | SEC FORM 4 Code D | —12,500 | filing |
| 20 May 2025filed 22 May 2025 | Metseraoption or derivative | SEC FORM 4 Code A | —46,875 at $0.00 | filing |
| 10 Feb 2025filed 26 Feb 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 10 Feb 2025filed 26 Feb 2025 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,250 at $0.00 | filing |
| 10 Feb 2025filed 26 Feb 2025 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 9 Feb 2024filed 13 Feb 2024 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 9 Feb 2024filed 13 Feb 2024 | LYEL Lyell ImmunopharmaBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Aug 2023filed 11 Aug 2023 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,250,000 at $0.00 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —220,000 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —87,050 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —152,110 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —170,396 | filing |
| 10 Mar 2023filed 10 Mar 2023 | Myovant Sciencesoption or derivative | SEC FORM 4 Code D | —90,310 | filing |
News
No headline names them, or the companies they trade most, lately.